Anaplastic glioma

Current Treatment Options in Neurology

Volumn 14, Issue 4, 2012, Pages 381-390

  Paleologos, Nina A ^a   Merrell, Ryan T ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NONE

Author keywords

Adjuvant temozolomide; Anaplastic astrocytoma; Anaplastic glioma; Anaplastic oligoastrocytoma; Anaplastic oligodendroglioma; Bevacizumab; Chemotherapy; Concomitant temozolomide; Molecular markers; PCV; Radiotherapy; Surgical resection; Treatment; Tumor

Indexed keywords

BEVACIZUMAB; CARBAMAZEPINE; IRINOTECAN; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CRANIOTOMY; DIGESTIVE SYSTEM PERFORATION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GLIOBLASTOMA; GLIOMA; HUMAN; HYPERTENSION; LYMPHOCYTOPENIA; NAUSEA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEINURIA; RADIATION DOSE; RECURRENT CANCER; THROMBOCYTOPENIA; THROMBOSIS; WOUND HEALING IMPAIRMENT;

EID: 84865866436     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0177-6     Document Type: Article

References (47)

1. Wen PY, Kesari S. Malignant gliomas in adults. NEngl J Med. 2008;359:492-507.
2. CBTRUS (2008). CBTRUS statistical report: Primarybrain and central nervous system tumors diagnosedin the United States in 2000-2004. Source: CentralBrain Tumor Registry of the United States, Hinsdale,IL. website:www.cbtrus.org.
3. Schild SE, Nisi K, Scheithauer BW, et al. The results ofradiotherapy for ependymomas: the Mayo Clinicexperience. Int J Radiat Oncol Biol Phys. 1998;42:953-8.
4. Vanuytsel L, Brada M. The role of prophylacticspinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys. 1991;21:825-30.
5. Ino Y, Betensky RA, Zlatescu MC, et al. Molecularsubtypes of anaplastic oligodendroglioma: implicationsfor patient management at diagnosis. ClinCancer Res. 2001;7:839-45.
6. Colman H, Aldape K. Molecular predictors in glioblastoma:toward personalized therapy. Arch Neurol. 2008;65:877-83.
7. Hegi ME, Diserens AC, Gorlia T, et al. MGMT genesilencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
8. McLendon R. Comprehensive genomic characterizationdefines human glioblastoma genes and corepathways. Nature. 2008;455:1061-8.
9. Friedman HS, Prados MD, Wen PY, et al. Bevacizumabalone and in combination with irinotecan inrecurrent glioblastoma. J Clin Oncol. 2009;27:4733-40.
10. Kreisl TN, Kim L, Moore K, et al. Phase II trial ofsingle-agent bevacizumab followed by bevacizumabplus irinotecan at tumor progression in recurrentglioblastoma. J Clin Oncol. 2009;27:740-5.
11. de Bont JM, den Boer ML, Kros JM, et al. Identificationof novel biomarkers in pediatric primitive neuroectodermaltumors and ependymomas byproteome-wide analysis. J Neuropathol Exp Neurol. 2007;66:505-16.
12. De Bustos C, Smits A, Stromberg B, et al. A PDGFRApromoter polymorphism, which disrupts the bindingof ZNF148, is associated with primitive neuroectodermaltumours and ependymomas. J Med Genet. 2005;42:31-7.
13. Lim M, Guccione S, Haddix T, et al. Alpha(v)beta(3)Integrin in central nervous system tumors. HumPathol. 2005;36:665-9.
14. Roma AA, Prayson RA. Expression of cyclo-oxygenase-2 in ependymal tumors. Neuropathology. 2006;26:422-8.
15. Gilbertson RJ, Bentley L,Hernan R, et al. ERBB receptorsignaling promotes ependymoma cell proliferationand represents a potential novel therapeutic target forthis disease. Clin Cancer Res. 2002;8:3054-64.
16. Hall WA, Merrill MJ, Walbridge S, Youle RJ. Epidermalgrowth factor receptors on ependymomasand other brain tumors. J Neurosurg. 1990;72:641-6.
17. Hegi ME, Liu L, Herman JG, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promotermethylation with clinical outcomes in glioblastomaand clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26:4189-99.
18. Wick W, Hartmann C, Engel C et al. NOA-04 randomizedphase III trial of sequential radiochemotherapyof anaplastic glioma with procarbazine,lomustine, and vincristine or temozolomide. J ClinOncol. 2009; 27:5874-5880.
19. Buccoliero AM, Castiglione F. Rossi Degl'Innocenti D et al. O6-Methylguanine-DNA-methyltransferase inrecurring anaplastic ependymomas: PCR and immunohistochemistry. J Chemother. 2008;20:263-8.
20. Miller CR, Dunham CP, Scheithauer BW, Perry A.Significance of necrosis in grading of oligodendroglialneoplasms: a clinicopathologic and genetic studyof newly diagnosed high-grade gliomas. J ClinOncol. 2006;24:5419-26.
21. McDonald JM, See SJ, Tremont IW, et al. The prognosticimpact of histology and 1p/19q status in anaplasticoligodendroglial tumors. Cancer. 2005;104:1468-77.
22. Cairncross JG, Ueki K, Zlatescu MC, et al. Specificgenetic predictors of chemotherapeutic response andsurvival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473-9.
23. Thiessen B, Maguire JA, McNeil K, et al. Loss of heterozygosityfor loci on chromosome arms 1p and10q in oligodendroglial tumors: relationship tooutcome and chemosensitivity. J Neurooncol. 2003;64:271-8.
24. Hartmann C, Meyer J, Balss J, et al. Type and frequencyof IDH1 and IDH2 mutations are related to astrocyticand oligodendroglial differentiation and age: a study of1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-74.
25. Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2mutations predict longer survival and response totemozolomide in low-grade gliomas. Neurology. 2010;75:1560-6.
26. van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but notpredictive for outcome in anaplastic oligodendroglialtumors: a report of the European Organizationfor Research and Treatment of CancerBrain Tumor Group. Clin Cancer Res. 2010; 16:1597-1604.
27. Hartmann C, Hentschel B, Wick W et al. Patients withIDH1 wild type anaplastic astrocytomas exhibit worseprognosis than IDH1-mutated glioblastomas, and IDH1mutation status accounts for the unfavorable prognosticeffect of higher age: implications for classification ofgliomas. Acta Neuropathol. 2010; 120: 707-718.
28. Sanai N, Polley MY, McDermott MW, et al. An extentof resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011;115:3-8.
29. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariateanalysis of 416 patients with glioblastomamultiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-8.
30. Metellus P, Figarella-Branger D, Guyotat J, et al. Supratentorial ependymomas: prognostic factors andoutcome analysis in a retrospective series of 46 adultpatients. Cancer. 2008;113:175-85.
31. Lassman AB, Iwamoto FM, Cloughesy TF et al. Internationalretrospective study of over 1000 adultswith anaplastic oligodendroglial tumors. NeuroOncol. 2011; 13: 649-659.
32. Cairncross G, Berkey B, Shaw E, et al. Phase III trial ofchemotherapy plus radiotherapy compared with radiotherapyalone for pure and mixed anaplastic oligodendroglioma. Intergroup Radiation TherapyOncology Group Trial 9402. J Clin Oncol. 2006;24:2707-14.
33. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvantprocarbazine, lomustine, and vincristineimproves progression-free survival but not overall survivalin newly diagnosed anaplastic oligodendrogliomasand oligoastrocytomas: a randomized EuropeanOrganisation for Research and Treatment of Cancerphase III trial. J Clin Oncol. 2006;24:2715-22.
34. Mikkelsen T, Doyle T, Anderson J et al. Temozolomidesingle-agent chemotherapy for newly diagnosedanaplastic oligodendroglioma. J Neurooncol. 2009; 92: 57-63.
35. Ducray F, del Rio MS, Carpentier C et al. Up-fronttemozolomide in elderly patients with anaplastic oligodendrogliomaand oligoastrocytoma. J Neurooncol. 2011; 101: 457-462.
36. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial oflocal chemotherapy with biodegradable carmustine(BCNU) wafers (Gliadel wafers) in patients with primarymalignant glioma. Neuro Oncol. 2003;5:79-88.
37. Wen PY, Brandes AA. Treatment of recurrent highgradegliomas. Curr Opin Neurol. 2009;22:657-64.
38. Tsao MN, Mehta MP, Whelan TJ, et al. The AmericanSociety for Therapeutic Radiology and Oncology(ASTRO) evidence-based review of the role of radiosurgery for malignant glioma. Int J RadiatOncol Biol Phys. 2005;63:47-55.
39. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapyfor anaplastic oligodendroglioma. NationalCancer Institute of Canada Clinical Trials Group. J ClinOncol. 1994;12:2013-21.
40. van den Bent MJ, Chinot O, Boogerd W, et al. Secondlinechemotherapy with temozolomide in recurrentoligodendroglioma after PCV (procarbazine, lomustineand vincristine) chemotherapy: EORTC BrainTumor Group phase II study 26972. Ann Oncol. 2003;14:599-602.
41. Chinot OL, Honore S, Dufour H, et al. Safety andefficacy of temozolomide in patients with recurrentanaplastic oligodendrogliomas after standard radiotherapyand chemotherapy. J Clin Oncol. 2001;19:2449-55.
42. Desjardins A, Reardon DA, Herndon 2nd JE, et al. Bevacizumab plus irinotecan in recurrent WHOgrade 3 malignant gliomas. Clin Cancer Res. 2008;14:7068-73.
43. Kreisl TN, Zhang W, Odia Y et al. A phase II trial ofsingle-agent bevacizumab in patients with recurrentanaplastic glioma. Neuro Oncol. 2011; 13: 1143-1150.
44. Perry JR, Belanger K, Mason WP et al. Phase II trial ofcontinuous dose-intense temozolomide in recurrentmalignant glioma: RESCUE study. J Clin Oncol. 2010; 28: 2051-2057.
45. Brandes AA, Cavallo G, Reni M, et al. A multicenterretrospective study of chemotherapy for recurrentintracranial ependymal tumors in adults by theGruppo Italiano Cooperativo di Neuro-Oncologia. Cancer. 2005;104:143-8.
46. Rehman S, Brock C, Newlands ES. A case report ofa recurrent intracranial ependymoma treated withtemozolomide in remission 10 years after completingchemotherapy. Am J Clin Oncol. 2006;29:106-7.
47. Freyschlag CF, Tuettenberg J, Lohr F, et al. Responseto temozolomide in supratentorial multifocal recurrenceof malignant ependymoma. Anticancer Res. 2011;31:1023-5.